Summary
The National Institute of Health in Iceland is conducting a population-based screening study for monoclonal gammopathy of undetermined significance (MGUS) and a randomized controlled trial of follow-up strategies to identify candidates for early treatment in multiple myeloma (MM).
1
The data from the iStopMM study could lead to a paradigm shift in MM therapy towards screening and early therapy.
1
High participation rates in the study could answer important questions on MGUS, including potential harms and benefits of screening.
2
According to
See more results on Neeva
Summaries from the best pages on the web
Summary
The Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) is a population-based screening study for monoclonal gammopathy of undetermined significance (MGUS) that is designed to identify candidates for early treatment in multiple myeloma (MM). The study is conducted by the National Institute of Health and is funded by the National Health Foundation. With a high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening, and could lead to a paradigm shift in MM therapy towards screening and early therapy.
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a ...
nature.com
The iStopMM program is an ambitious research project supported by the International Myeloma Foundation (IMF) and led by Sigurdur Kristinsson (Professor of Hematology, University of Iceland — Reykjavik, Iceland). Started…
iStopMM | International Myeloma Foundation
myeloma.org
Dr. Sigurdur Yngvi Kristinsson, Professor at the University of Iceland and the study’s principal investigator receives the Brian G.M. Durie Outstanding Achievement Award for outstanding research in the field of…
Homepage - iStopMM
istopmm.com
